Transcatheter Aortic Valve Implantation for Stenosed and Regurgitant Aortic Valve Bioprostheses. CoreValve for Failed Bioprosthetic Aortic Valve Replacements

J Am Coll Cardiol. 2010; 55(2):97-101

Muhammed Z. Khawaja, Peter Haworth, Azad Ghuran, Lorraine Lee, Adam de Belder, Neville Hutchinson, Uday Trivedi, Jean-Claude Laborde, David Hildick-Smith

Transcatheter aortic valve implantation is increasingly being used to treat severe aortic stenosis in patients with high operative risk. In an aging population the incidence of aortic stenosis is rising, and increasing numbers of elderly patients are undergoing aortic valve replacement with bioprosthetic valves. Therefore, there is a corresponding increase in prosthetic degeneration. This presents cardiologists with a cohort of patients for whom the risk of re-do aortic valve surgery is prohibitive. We present the first series of such patients with degenerative bioprosthetic stenosis or regurgitation successfully treated with CoreValve (Medtronic, Luxembourg) implantation.

PMID:

One Response

  1. Paul Schoenhagen, MD  on January 5th, 2010

    Valve-in-valve implantation is another emerging application of this new technology, as imaging plays a critical role.

    See recent post:
    Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Implantation with the Medtronic-Corevalve Bioprosthesis.
    Hasan Jilaihawi, Derek Chin, Tomasz Spyt, Mohamed Jeilan, Mariuca Vasa-Nicotera, Johan Bence, Elaine Logtens, Jan Kovac.
    European Heart Journal. 2009; 119(1):1034-1048.
    PMID: 20037145


Leave a Reply